Skip to main content
JNJ
NYSE Life Sciences

欧洲委员会批准强生公司的AKEEGA用于治疗BRCA1/2突变性前列腺癌

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$242.7
Mkt Cap
$584.882B
52W Low
$141.5
52W High
$251.71
Market data snapshot near publication time

summarizeSummary

欧洲委员会已授予强生公司的药物AKEEGA用于治疗BRCA1/2突变性前列腺癌的批准。这一重要的监管里程碑允许强生公司在整个欧盟范围内销售AKEEGA，扩大其肿瘤学产品组合和在关键治疗领域的收入潜力。这一批准是在强生公司最近获得多个积极的监管消息之后，包括Nipocalimab获得FDA Fast Track指定和Tecvayli获得FDA批准，表明该公司的制药管道取得了强劲的进展。AKEEGA在欧洲的商业化预计将对强生公司的未来收益做出积极贡献，进一步巩固其在竞争激烈的肿瘤学市场的地位。投资者将关注在该地区的推出细节和销售增长情况。

在该公告发布时，JNJ的交易价格为$242.70，交易所为NYSE，所属行业为Life Sciences，市值约为$5848.8亿。 52周交易区间为$141.50至$251.71。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed JNJ - Latest Insights

JNJ
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Imaavy Secures FDA Priority Review for Rare Blood Disorder
Sentiment: Positive
View Wiseek Article
JNJ
Apr 24, 2026, 9:12 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J Acquires Atraverse Medical to Bolster Cardiac Device Portfolio
Sentiment: Positive
View Wiseek Article
JNJ
Apr 22, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
J&J Reports Strong Q1 Operational Sales Growth, Raises Dividend Amidst Talc Litigation Challenges and Increased Net Debt
Sentiment: Neutral
View Wiseek Article
JNJ
Apr 22, 2026, 10:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Nipocalimab-aahu Phase 3 Study Shows Sustained Improvements for Autoantibody Disease
Sentiment: Positive
View Wiseek Article
JNJ
Apr 17, 2026, 6:47 PM EDT
Source: Reuters
Importance Score:
8
Judge Rejects Bayer's Bid to Block J&J's Multibillion-Dollar Prostate Cancer Drug Claims
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 4:07 PM EDT
Source: Wiseek News
Importance Score:
8
J&J Talc Bankruptcy Plan Voided by Court, Reopening Lawsuits; Q1 Revenue Hits $24B, Guidance Raised
Sentiment: Negative
View Wiseek Article
JNJ
Apr 14, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Johnson & Johnson Reports Strong Q1, Raises 2026 Guidance, and Increases Dividend for 64th Consecutive Year
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 6:20 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Innovative Medicine Sales Growth Fueled by Darzalex, Carvykti, Erleada, Rybrevant, Tremfya, and Spravato
Sentiment: Positive
View Wiseek Article
JNJ
Apr 13, 2026, 12:44 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Johnson & Johnson Q1 Sales Expected Up, Profit Down Ahead of Earnings Report
Sentiment: Neutral
View Wiseek Article
JNJ
Mar 30, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
J&J Secures $500M R&D Pact for JNJ-4804, Reports 71% ORR for JNJ-1900 in NSCLC Trial
Sentiment: Positive
View Wiseek Article